The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

Drug resistance continues to be a major factor in limiting the effectiveness of cancer chemotherapy. Evidence from a variety of sources implicates a genetic basis for most drug-resistant phenotypes. Assuming a random spontaneous origin for these resistant cells, it is possible to develop mathematical and computer-based models of the drug treatment of tumors. These can provide a more intuitive understanding of the basis of treatment success or failure. This in turn may lead to the development of more rational and effective treatment protocols. Studies of phenomena such as pleiotropic drug resistance are providing insights into how multiple levels of drug resistance occur and are yielding information on how certain types of drug resistance may be prevented or overcome.

[1]  R. Simon,et al.  Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. , 1979, Cancer treatment reports.

[2]  J. Ziegler,et al.  Burkitt's lymphoma--a model for intensive chemotherapy. , 1977, Seminars in oncology.

[3]  Y. Hayashida,et al.  Surgical Adjuvant Chemotherapy for Gastric Cancer , 1986 .

[4]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[5]  I. Todd,et al.  Pharmacological Basis of Cancer Chemotherapy , 1976, British Journal of Cancer.

[6]  M. Delbrück,et al.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.

[7]  J. Bertino,et al.  Genetic transformation of murine bone marrow cells to methotrexate resistance. , 1983, Blood.

[8]  A. Varshavsky.  Phorbol ester dramatically increases incidence of methotrexate-resistant mouse cells: Possible mechanisms and relevance to tumor promotion , 1981, Cell.

[9]  T. Tsuruo.  Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. , 1983, Cancer treatment reports.

[10]  R. Sutherland,et al.  Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. , 1971, Journal of the National Cancer Institute.

[11]  B. Spengler,et al.  Metaphase chromosome anomaly: association with drug resistance and cell-specific products. , 1976, Science.

[12]  J. Goldie,et al.  Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells. , 1981, The Journal of biological chemistry.

[13]  W. Salser,et al.  Gene transfer in intact animals , 1980, Nature.

[14]  J. Goldie,et al.  A model for the resistance of tumor cells to cancer chemotherapeutic agents , 1983 .

[15]  J. Goldie,et al.  Overproduction of two antigenically distinct forms of dihydrofolate reductase in a highly methotrexate-resistant mouse leukemia cell line. , 1983, Cancer research.

[16]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[17]  F. Ruddle,et al.  Production and Characterization of Proliferating Somatic Cell Hybrids , 1973 .

[18]  D. Haber,et al.  Chromosome-mediated transfer and amplification of an altered mouse dihydrofolate reductase gene , 1982, Somatic cell genetics.

[19]  W. T. Beck,et al.  Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. , 1982, Cancer research.

[20]  S. Shackney,et al.  Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. , 1978, Annals of internal medicine.

[21]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[22]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[23]  R. Worton,et al.  Evidence obtained by induced mutation frequency analysis for functional hemizygosity at theemt locus in CHO cells , 1979, Somatic cell genetics.

[24]  S. Beverley,et al.  Rapid spontaneous dihydrofolate reductase gene amplification shown by fluorescence-activated cell sorting. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Riordan,et al.  Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. , 1979, The Journal of biological chemistry.

[26]  J. Till,et al.  QUANTITATION OF CELLULAR RADIOBIOLOGICAL RESPONSES. , 1964, Annual review of nuclear science.

[27]  E. Frei.  The National Cancer Chemotherapy Program. , 1982, Science.

[28]  K. Bagshawe.  Risk and prognostic factors in trophoblastic neoplasia , 1976, Cancer.

[29]  H. Skipper,et al.  Establishment of cross-resistance profiles for new agents. , 1983, Cancer treatment reports.

[30]  A. R. Crane,et al.  Primary Osteogenic Sarcoma of Bladder , 1944 .

[31]  R. Schimke,et al.  Chromosomal and extrachromosomal localization of amplified dihydrofolate reductase genes in cultured mammalian cells. , 1981, Cold Spring Harbor symposia on quantitative biology.

[32]  A. Santoro,et al.  Alternating drug combinations in the treatment of advanced Hodgkin's disease. , 1982, The New England journal of medicine.

[33]  D. Alberts,et al.  Clinical correlations of in vitro drug sensitivity. , 1980, Progress in clinical and biological research.

[34]  F. Miller,et al.  Tumor subpopulation interactions in neoplasms. , 1983, Biochimica et biophysica acta.

[35]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[36]  J. Bertino,et al.  Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. , 1978, Cold Spring Harbor symposia on quantitative biology.

[37]  B. Spengler,et al.  Drug resistance in Chinese hamster lung and mouse tumor cells. , 1983, Cancer treatment reports.

[38]  J. Kraut,et al.  Directed mutagenesis of dihydrofolate reductase. , 1983, Science.

[39]  G R Stark,et al.  Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. , 1979, The Journal of biological chemistry.

[40]  R. Demars.  Resistance of cultured human fibroblasts and other cells to purine and pyrimidine analogues in relation to mutagenesis detection. , 1974, Mutation research.

[41]  J. Schornagel,et al.  Gene amplification and altered enzymes as mechanisms for the development of drug resistance. , 1983, Cancer treatment reports.

[42]  L. Siminovitch.  On the nature of hereditable variation in cultured somatic cells , 1976, Cell.

[43]  D. Haber,et al.  Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. , 1981, The Journal of biological chemistry.

[44]  R. Stallings,et al.  Multidrug-resistant phenotype cosegregates with an amplified gene in somatic cell hybrids of drug-resistant Chinese hamster ovary cells and drug-sensitive murine cells , 1986, Molecular and cellular biology.

[45]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.

[46]  L. Einhorn,et al.  Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. , 1979, Seminars in oncology.

[47]  R. Hill,et al.  Biologic discussions augmenting radiation effects and model systems , 1975, The Laryngoscope.

[48]  W. Mackillop,et al.  Measurement of self-renewal in culture of clonogenic cells from human ovarian carcinoma. , 1981, British Journal of Cancer.

[49]  H. David,et al.  Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. , 1970, Applied microbiology.

[50]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[51]  E. Geissler,et al.  Cycloheximide resistance in Chinese hamster cells. I. Spontaneous mutagenesis. , 1975, Mutation research.